Another of PepGen’s trials has encountered resistance from the FDA, with the regulator now putting the company’s plans to ...

Foghorn Therapeutics has finally given up on its only wholly-owned clinical-stage candidate after the troubled cancer drug ...

After its eye disease antibody flopped in an FDA-requested clinical trial in late November, Outlook Therapeutics is ...

Edgewise Therapeutics’ lead candidate has been shown to reduce levels of a biomarker related to skeletal muscle damage in a ...

PureTech’s only internal drug program has slowed lung function decline in a phase 2 trial in idiopathic pulmonary fibrosis ...

Discover how the Inventus Connect eSIM solutions, designed specifically for provisioned devices in clinical trials, are ...

Pharming is paying $66.1 million to acquire Swedish biotech Abliva and its phase 2-stage med that the Dutch drugmaker ...

Gilead Sciences has raided Sanofi for its next chief medical officer, luring Dietmar Berger, M.D., Ph.D., away from the ...

The U.S. Preventive Services Task Force pitched an update to its guidelines for cervical cancer screening, endorsing HPV ...

Cardiff Oncology’s investigational PLK1 inhibitor paired with standard-of-care treatment showed a 64% overall response rate ...

Incyte is dropping a program for patients with myelofibrosis-related anemia after its investigational small molecule failed ...

Emma Reeve, the chair of Editas’ board, is also resigning, to be replaced by Jessica Hopfield, Ph.D., the company explained ...